The results from a research partnership between GE HealthCare and Vanderbilt University Medical Center (VUMC) utilizingArtificial intelligence (AI) to enable safer and more precise cancer immunotherapies show that the models predict patient responses with 70% to 80% accuracy.
The researchers retrospectively analyzed and correlated the immunotherapy treatment responses of thousands of deidentified VUMC cancer patients according to demographic, genomic, tumor, cellular, proteomic and imaging data. They designed AI models to predict efficacy outcomes and the likelihood of an individual patient developing an adverse reaction — providing information that may help clinicians select the most appropriate treatment pathway sooner while potentially sparing unnecessary side effects and costs.
【MORE】